Edition:
India

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
22 Jun 2018
Change (% chg)

$0.03 (+2.36%)
Prev Close
$1.27
Open
$1.28
Day's High
$1.30
Day's Low
$1.25
Volume
70,389
Avg. Vol
51,234
52-wk High
$5.99
52-wk Low
$1.23

Chart for

About

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue... (more)

Overall

Beta: 2.34
Market Cap(Mil.): $69.25
Shares Outstanding(Mil.): 165.83
Dividend: --
Yield (%): --

Financials

BRIEF-CytRx Announces Closing Of $7.0 Mln Registered Direct Offering

* CYTRX ANNOUNCES CLOSING OF $7.0 MILLION REGISTERED DIRECT OFFERING Source text for Eikon: Further company coverage:

16 May 2018

BRIEF-Cytrx Announces $7.0 Million Registered Direct Offering

* CYTRX - ENTERED PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO SELL IN REGISTERED DIRECT OFFERING 5.6 MILLION SHARES AT PRICE OF $1.25/SHARE Source text for Eikon: Further company coverage:

11 May 2018

BRIEF-Cytrx Reports First Quarter Loss Of $0.15 Per Share

* CASH AND CASH EQUIVALENTS OF $35.1 MILLION AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

08 May 2018

BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug Candidates

* CYTRX PRESENTS STATISTICALLY SIGNIFICANT BREAKTHROUGH DATA FOR ITS ALBUMIN BINDING ULTRA HIGH POTENCY LADR DRUG CANDIDATES

18 Apr 2018

BRIEF-CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials

* CYTRX SELECTS FOUR NEW LADR™ ULTRA HIGH POTENCY DRUG CANDIDATES FOR ADVANCEMENT TOWARD CLINICAL TRIALS

15 Mar 2018

BRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum Partners

* CYTRX CORP - ANNOUNCED ITS ENTRY INTO A DEFINITIVE AGREEMENT WITH DESTUM PARTNERS

28 Feb 2018

Earnings vs. Estimates